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SUMMARY 
 
A 7-year-old, intact female Domestic Shorthair cat was referred to University Veterinary Hospital (UVH), UPM for 
diagnostic workup of a hepatomegaly observed on abdominal radiographs. Physical examination revealed no significant findings 
except for a distended abdomen. Hematology and serum biochemistry findings included a regenerative anaemia, left shift 
neutrophilia and a 10-fold elevation in gamma-glutamyltranspeptidase (GGT). Abdominal ultrasound revealed heterechoic liver 
lobes with irregular margins and presence of nodular and cyst-like structures predominantly affecting the left lobes.  A mild ascites 
was also noted. A fine needle aspiration of the liver was performed and cytology results confirmed a cholangiocarcinoma. Generally, 
the outcome for cholagiocarcinoma is poor and there is limited information regarding the prognosis for patients with 
cholangiocarcinoma following chemotherapy or surgery.  
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INTRODUCTION  
 
The prevalence of primary hepatobiliary neoplasia in 
cats accounts for 1.5-2.3% of all feline neoplasia 
(Balkman, 2009). Primary hepatobiliary neoplasia is more 
common than metastatic disease in cats while in dogs liver 
metastases are more frequent (Pastor and Palnellas, 2013). 
Primary hepatobiliary neoplasia can develop from 
the hepatocytes (hepatocellular adenoma, hepatocellular 
carcinoma); bile duct epithelium (biliary adenoma, biliary 
carcinoma); neuroendocrine cells (neuroendocrine 
carcinoma or carcinoid); or stromal cells (sarcomas). 
Other neoplastic conditions that often involve the liver 
include lymphoma, disseminated histiocytic sarcoma, and 
systemicmastocytosis (Balkman, 2009). 
Bile duct neoplasia can be further divided into 
cholangioadenoma and cholangiocarcinoma. 
Cholangioadenomas are benign tumours which are 
common in cats, accounting for 32-52% of all feline 
hepatobiliary neoplasia. Also known as biliary or cyst 
adenomas due to their cystic appearance. 
Cholangioadenomas usually do not cause clinical signs 
until they reach a large size and compress adjacent organs 
(Liptak, 2006; Pastor and Palnellas, 2013). Moreover, 
malignant transformation of cholangioadenoma has been 
reported in humans and cats (Adler and Wilson, 1995). 
Cholangiocarcinoma is the most common malignant 
hepatobiliary tumour in cats and the second most common 
in dogs (Liptak, 2006; Pastor and Palnellas, 2013). It can 
be intrahepatic, extrahepatic, or within the gallbladder. 
Intrahepatic carcinomas are more common in dogs, 
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while an equal distribution of intrahepatic and 
extrahepatic carcinomas has been reported in cats. 
However, bile duct carcinoma of the gallbladder is rare in 
both species (Lawrence et al., 1994; Cullen and Popp, 
2002; Liptak, 2006). 
Cholangiocarcinomas have an aggressive biologic 
behavior. Metastasis is common in dogs with up to 88% 
metastasising to the regional lymph nodes and lungs and 
other sites including the heart, spleen, adrenal glands, 
pancreas, kidneys, and spinal cord (Lawrence et al., 1994; 
Cullen and Popp, 2002; Liptak, 2006; Pastor and 
Palnellas, 2013). In cats, diffuse intraperitoneal metastasis 
occurs in 67-80% of the cases (Lawrence et al., 1994). 
Three morphologic forms have been descripted: 
lobular, multifocal and diffuse. Massive form involving a 
large mass in one lobe, nodular with discrete nodules in 
several lobes, or diffuse where the entire liver or part of it 
is infiltrated with neoplastic cells. In general, only the 
lobular form should be considered for surgical removal as 
long as there is no evidence of metastasis. The prognosis 
for multifocal and diffuse cholangiocarcinoma is poor, 
and surgery usually is not feasible (Balkman, 2009; Pastor 
and Palnellas, 2013). Unfortunately, there is no effective 
chemotherapeutic options for cholangiocarcinoma in cats 
and dogs.  
 
CASE REPORT 
 
A 7-year-old, spayed female Domestic Shorthair cat 
was referred to University Veterinary Hospital (UVH), 
UPM for diagnostic workup of a hepatomegaly as 
observed on abdominal radiographs (Figure 1 & 2). She 
was kept with another 50 cats at home, indoor, and fed 
with commercial dry food. The owner noticed the cat was 
having distended abdomen 1 week prior to presentation 
and taken to a private veterinary clinic. Clinically the cat 
was doing fine. Physical examination findings revealed 
all vital signs were within the normal range, the cat had a  
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Figure 1. Lateral abdominal radiograph with an 
enlarged liver 
 
 
 
 
 
 
 
 
 
Figure 2. Dorsoventral 
view of the abdominal 
radiograph with an 
enlarged liver 
 
distended abdomen and a hard mass was palpated at the 
cranial abdomen. 
Haematology results showed there was a mildly 
regenerative anaemia with PCV 0.22 L/L (reference 
range: 0.24-0.45 L/L) with reticulocytes 1.6/100 RBC 
(reference range: 0.5-1.5/100 RBC); neutrophilia with left 
shift (segmented neutrophils 21.13 × 109/L, reference 
range: 2.5-12.5 × 109/L; band neutrophils 0.56 × 109/L, 
reference range: <0.3 × 109/L) and monocytosis (1.11 × 
109/L, reference range: 0.2-0.8 × 109/L). Serum 
biochemistry revealed a 10-fold elevation in gamma-
glutamyltranspeptidase (GGT) (68 U/L, reference range is 
<6.0 U/L) indicative of cholestasis or biliary hyperplasia. 
From the blood result, hepatobiliary disease was evident. 
Patients with hepatobiliary disease can be anaemic as a 
result of gastrointestinal bleeding secondary to pressure 
changes in the liver.  
Thoracic radiographs were taken for metastatic 
check. However, there were no signs of metastasis 
observed upon thoracic radiography. Abdominal 
ultrasonography revealed heterechoic liver lobes with 
irregular margins and presence of nodular and cyst-like 
structures predominantly affecting the left lobes (Figure 
3). A mild ascites was also noted. Therefore, a fine needle 
aspiration of the liver was performed. Cytology showed a 
dense aggregate of large epithelial cells with minimal 
cytoplasm, the fine bluish granules in the cytoplasm of the 
hepatocytes were consistent with lipofuscin pigment 
(Figure 4). The cytology result confirmed a 
cholangiocarcinoma. 
The only treatment for cholangiocarcinoma is 
surgical removable, however in this case more than ¾ of 
liver was affected therefore lobectomy was not feasible. 
Chemotherapy for liver neoplasia is questionable. 
Therefore, only liver supplement (Liv 52 PO BID) was 
 
Figure 3. (Left) Abdominal ultrasonography findings 
were nodular structures on the liver 
Figure 4. (Right) Cytology: a cluster of epithelial cells 
with multiple nucleoli 
 
 
Figure 5. (Top left) Cat presented with distended 
abdomen with thinning of skin after one month; (Top 
right and bottom left) Abdominal radiograph after one 
month, loss of serosal details  
 
given in order to slow down the oxidative damage. The 
cat deteriorated progressively. She became cachexic, the 
abdomen distension worsened, she became hyporexic and 
developed polyuria-polydipsia after one month (Figure 5).  
Abdominocentesis was performed in order to reduce 
the discomfort and 400 mL of hemorrhagic exudate was 
removed. After one month, abdominal radiography and 
blood tests were repeated. Abdominal radiography 
showed general loss of serosal details (Figure 5). 
Complete blood count showed moderate 
thrombocytopenia (112 × 109/L, reference range: 300-700 
× 109/L). Thrombocytopaenia can be due to decreased 
thrombopoeitin production or increased thrombocyte 
consumption due to gastrointestinal bleeding. Serum 
biochemistry results showed all the liver enzymes were 
decreased to lower limit (alanine aminotransferase 17.5 
U/L, reference range: 10-90 U/L; alkaline phosphatase 27 
U/L, reference range: <80 U/L; gamma-
glutamyltranspeptidase 43U/L , reference range : <6 U/L). 
Decreased liver enzymes values could be the indicative of 
loss of liver mass. The owner was advised to consider the 
option of euthanasia due to the deteriorating condition, but 
the owner chose to spend some quality time with the cat.  
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DISCUSSION 
 
The liver has significant structural and functional 
reserve capacity to support ongoing metabolic needs 
during liver injury. Since the liver has 80% reserve 
capacity, symptoms occur only in progressive disease 
whereby the hepatic reserve has been exhausted. Diseases 
often remain subclinical for long periods of time. As in 
this case, although most of the liver lobes were affected, 
the cat was clinically still doing fine and did not show any 
clinical signs initially. However, when the functional 
reserve was exhausted, the cat deteriorated very fast. 
In humans, the risk factors for cholangiocarcinoma 
include trematode infestation, cholelithiasis, and 
sclerosing cholangitis (Boris and Gores, 2008). Trematode 
infestation such as Clonorchis sinensis and Opistorchis 
viverrini associated with the development 
cholangiocarcinoma are well defined in humans (Sripa et 
al., 2007). Trematode infestation may also be one of the 
risk factors for the development of cholangiocarcinoma in 
cats and dogs. Platynosum fastosum infestation has been 
reported to cause  cholangiocarcinomas  in  cats  
suggesting  an  association  between  the  parasitic  
infection and  the  carcinogenesis,  probably preceded  by  
dilation and  thickening  of  the  biliary  duct  walls,  
ductal  epithelium hyperplasia,  and  fibrosis (Andrade et 
al., 2012). 
Generally, most hepatobiliary neoplasia shows the 
same clinical symptoms. Clinical signs and laboratory 
signs are nonspecific. The most common presenting signs 
are nonspecific, such as inappetence, weight loss, 
lethargy, vomiting, polydipsia-polyuria, and ascites 
(Cullen and Popp, 2002; Liptak, 2006). In this case, the 
first clinical sign seen was ascites, and progressively the 
cat showed other symptoms such as inappetance, weight 
loss and polyuria, polydipsia. Hematologic and serum 
biochemical abnormalities are usually nonspecific. For the 
laboratory tests, only GGT was increased in this case, 
indicative of biliary disease and is not very helpful in 
making a diagnosis.  
Liver lobectomy is recommended for cats and dogs 
with massive bile duct carcinoma. However, survival time 
has been poor in cats and dogs treated with liver 
lobectomy as the majority died within 6 months due to 
local recurrence and metastatic disease (Lawrence et al., 
1994).There is no known effective treatment for cats and 
dogs with nodular or diffuse bile duct carcinomas as these 
lesions are not amenable to surgical resection and other 
treatments are often not successful (Pastor and Palnellas, 
2013). 
In human medicine, systemic chemotherapy used for 
cholangiocarcinoma includes single agent gemcitabine; 
combination of gemcitabine and cisplatin; gemcitabine 
and oxaliplatin; combination of epirubicin, cisplatin and  
5-fluorouracil; oxaliplatin and cisplatin; and combination 
of sorafenib with lapatinib or bevacizumab (Marsh et al., 
2012). However benefits of chemotherapy are still 
uncertain owing to the lack of truly effective 
chemotherapy. In veterinary medicine, a gemcitabine-
carboplatin combination hasbeen described for cats with 
carcinoma (Martinez-Ruzafa et al., 2009).However, a 
gemcitabine-carboplatin combination was showed to be 
more effective for cats with pancreatic carcinoma. 
Whereas, this combination appears moderately well 
tolerated in cats; usage of this combination still limited 
due to lack of proper dosing and treatment schedules 
(Martinez-Ruzafa et al., 2009). 
Novel treatment such as chemoembolization, 
microbrachytherapy and antiangiogenic therapy havebeen 
described in human medicine as treatment options for 
hepatobiliary neoplasia. Microbrachytherapy is an 
intraarterialradio embolization using microspheres 
incorporated with the high energy radionuclideyttrium-90 
which is a potential treatment option for patients with 
unrestectable neoplasia. Once infused, these microspheres 
traverse the hepatic vascular plexus and selectively 
implant within the tumour arterioles. Embedded within 
the arterioles, the impregnated microspheres emit high 
energy and low penetrating radiation doses selectively to 
the tumour and causing tumour cell necrosis (Bult et al., 
2012). In one pilot study, 3 cats with unresectable liver 
tumours (hepatocellular carcinoma, cholangiocarcinoma 
and malignant epithelial liver tumour) were included (Bult 
et al., 2013).A rather different approach from intraarterial 
microsphere implantation, this study directly injected 
radionuclide microsphere into the tumour. All cats 
improved markedly after treatment and most biochemical 
and hematologic parameters normalized shortly after 
treatment. However, these cats were euthanized few 
months later owing to disease progression. This technique 
might not be able to prolong the median survival time, but 
it indicated that holmium 166 acetylacetone microsphere 
is safe to use and the potential of its’ use as a novel 
intratumoural radioablation device especially for 
unresctable malignant tumours. 
 
CONCLUSION 
 
Cholangiocarcinoma is a malignant tumour which 
commonly occurs in old animals. Prognosis for this case 
was guarded as most of the liver lobes were affected and 
generally the outcome for cholagiocarcinoma is poor. 
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